Neos Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference

DALLAS and FORT WORTH, Texas, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products, today announced that Jerry McLaughlin, chief executive officer, will present a company overview at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 2, 2019 at 9:30 a.m. ET in New York, NY.

A live webcast of the presentation will be available on the Investor Relations page of the Company’s website at http://investors.neostx.com/. Following the presentation, a replay of the webcast will be available on Neos’ website for 30 days. 

About Neos Therapeutics Neos Therapeutics, Inc. (Nasdaq: NEOS) is a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products. The Company has three approved produced, all for the treatment of ADHD, that utilize the Company’s extended-release technology platform: Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is available at www.neostx.com.

CONTACTS:

Richard I. EisenstadtChief Financial OfficerNeos Therapeutics(972) 408-1389[email protected]

Sarah McCabe Investor Relations Stern Investor Relations, Inc. (212) 362-1200 [email protected]

You May Also Be Interested In

• At UN General Assembly, Global Autism Advocacy Coalition launches new initiatives to accelerate autism action worldwide
• BNB Price Prediction: BNB Holds Near $774 as Remittix Sets a $0.46 Final Stage Above Its $0.21 Entry
• XRP Price Prediction: ETFs Add $38 Million in Two Days as Pepeto 100x Presale Heats Up